Glucosamine and chondroitin have been fixtures of the UK pharmacy supplement aisle for more than two decades. Combined tablets, standalone glucosamine sulphate, "joint care" blends and branded tinctures all target the same customer: an adult with knee pain hoping to slow the grinding progression of osteoarthritis without long-term painkillers.

In 2026 the clinical picture is the same it has been for much of the last ten years. Trials are mixed. The most methodologically robust ones are negative. NICE guideline NG226 on osteoarthritis explicitly advises against offering glucosamine or chondroitin on the NHS. The NHS osteoarthritis page is equally clear.

This is a pharmacy-counter guide to what the evidence actually shows, how to have the conversation, and what works instead.

Where the two supplements came from

Glucosamine is an amino sugar that the body uses to build glycosaminoglycans and proteoglycans — components of cartilage. Chondroitin sulphate is one of those glycosaminoglycans. The theoretical case for supplementation is straightforward: provide precursors of cartilage matrix and hope the joint rebuilds what osteoarthritis erodes.

The theoretical case has struggled to translate into clinically meaningful trial results. Cartilage is avascular and low-turnover, which makes it resistant to dietary intervention at the adult stage of disease. Absorption and joint-space delivery of oral glucosamine are poorly characterised. The evidence base is large but heterogeneous, with consistent signals of publication bias towards industry-sponsored trials.

The landmark trials

GAIT (Glucosamine/Chondroitin Arthritis Intervention Trial) randomised 1,583 US patients with knee osteoarthritis to glucosamine hydrochloride 1,500 mg, chondroitin sulphate 1,200 mg, the combination, celecoxib or placebo for 24 weeks. The primary finding was no significant benefit for the supplements over placebo on the primary pain outcome. A subgroup analysis hinted at a possible benefit in moderate-to-severe pain, but the study was not powered to confirm it.

LEGS (Long-term Evaluation of Glucosamine Sulfate) and several other trials tested glucosamine sulphate (a different salt from the hydrochloride used in GAIT) in European populations, with mixed results. Some industry-sponsored trials reported benefit on pain and joint-space narrowing. Independent analyses — including Cochrane's review of chondroitin for osteoarthritis — note that when trials are weighted by methodological quality, the effect shrinks towards placebo.

NICE reviewed this body of evidence and concluded in NG226 that neither supplement should be offered for managing osteoarthritis. NICE CKS offers the same advice.

What the counter conversation should cover

A customer asking for glucosamine and chondroitin is usually telling a story that is easy to recognise: gradually worsening knee pain over months or years, now limiting walking or sleep, and a wish to avoid daily painkillers. The evidence-based pharmacy response goes beyond "there's no evidence" — because that leaves the patient with no alternative and often a renewed determination to try it anyway.

A structured counter approach:

1. Acknowledge the problem. Osteoarthritis is real, common and under-treated.
2. Name the evidence honestly. Tell the customer that the best-quality trials, including GAIT, have not shown a benefit over placebo, and that NICE does not recommend them for this reason.
3. Explain the safety side. Glucosamine and chondroitin are generally well tolerated. If they want to try a short course, they are unlikely to come to harm.
4. Offer the evidence-based alternatives. This is where the pharmacy adds value.

What the evidence supports for knee osteoarthritis

NICE NG226 and NHS guidance recommend, in order of priority:

• Weight management where BMI is elevated — each kilogram lost reduces knee load several-fold over a walking day.
• Therapeutic exercise, particularly quadriceps strengthening and low-impact aerobic activity.
• Topical NSAIDs as first-line pharmacological treatment for knee osteoarthritis — covered in detail in our topical NSAID gels and topical diclofenac vs ibuprofen articles.
• Oral NSAIDs for short courses when topical is inadequate, with consideration of gastric protection and cardiovascular risk.
• Paracetamol as a modest-effect adjunct, though NICE downgraded its role in recent updates.
• Capsaicin cream for localised persistent pain — see our capsaicin cream for joint pain guide.
• Intra-articular steroid injection for acute flare, via GP or physiotherapy referral.
• Surgical referral when conservative options are exhausted.

A pharmacy counter that walks a customer from glucosamine through this list, and actively dispenses or recommends the topical NSAID, is delivering real clinical value.

Safety points for those who still want to try

Glucosamine and chondroitin are generally well tolerated. A handful of counter cautions are worth knowing:

• Glucosamine is derived from shellfish in many UK products — shellfish-allergic customers should choose a vegetarian source or avoid.
• Diabetes — older concerns about glucosamine worsening glucose control have not been borne out in clinical trials, but advise patients to monitor blood glucose if they have diabetes.
• Warfarin — case reports of INR rise with glucosamine and glucosamine–chondroitin combinations exist. Anticoagulated patients should check INR more closely if starting.
• Pregnancy and breastfeeding — not recommended, as data are limited.
• Duration — if there is no subjective benefit after three months, stopping is reasonable. Effects that appear after a year of supplementation are hard to distinguish from natural fluctuation of osteoarthritis symptoms.

Further reading on PharmSee

• Topical NSAID gels for musculoskeletal pain
• Topical diclofenac vs ibuprofen
• Capsaicin cream for joint pain
• Collagen supplements: the evidence on skin, joints and hair

Find a UK community pharmacy on PharmSee.

Sources and caveats

Content drawn from NICE NG226 on osteoarthritis, NICE CKS, NHS osteoarthritis guidance and the Cochrane review of chondroitin. The trial base is heterogeneous and industry sponsorship is a recurrent limitation of the positive studies. This article is general pharmacy guidance for the UK, not personalised medical advice.